Nausea Treatment for Migraine in Teenagers

Treatment Algorithm Based on Nausea Severity

The American Academy of Neurology recommends using a non-oral triptan, such as sumatriptan nasal spray 5-20 mg or zolmitriptan nasal, or adding an antiemetic, such as metoclopramide 10 mg or prochlorperazine, to oral therapy for nausea in adolescent migraine patients 1
For mild nausea, adding metoclopramide 10 mg orally to ibuprofen (7.5-10 mg/kg) taken at headache onset is recommended, as metoclopramide provides dual benefit by treating nausea and providing direct analgesic effects through central dopamine receptor antagonism 1, 2
Metoclopramide provides independent pain relief beyond its antiemetic properties, making it a beneficial addition to analgesic therapy 2, 3

The American Academy of Neurology recommends switching to a non-oral triptan, such as sumatriptan nasal spray 5-20 mg, immediately for moderate to severe nausea or early vomiting, as non-oral routes bypass gastric stasis that occurs during migraine attacks 1
Alternative options include zolmitriptan nasal spray if sumatriptan nasal is ineffective after 2-3 attacks 1

The American Academy of Emergency Medicine recommends IV metoclopramide 10 mg plus IV ketorolac 30 mg as first-line combination therapy for severe nausea requiring emergency/urgent care treatment, providing rapid pain relief while treating nausea 2
Alternative options include IV prochlorperazine 10 mg, which has comparable efficacy to metoclopramide with a lower adverse event rate 2, 4

The American Headache Society recommends limiting all acute migraine medications, including antiemetics, to no more than 2 days per week to prevent medication-overuse headache 1, 2, 4
If a teenager needs acute treatment more than twice weekly, preventive therapy should be initiated immediately, such as amitriptyline combined with cognitive behavioral therapy, topiramate, or propranolol 1

Metoclopramide is contraindicated in patients with pheochromocytoma, seizure disorder, GI bleeding, or GI obstruction, and carries a risk of extrapyramidal reactions 2
Prochlorperazine is contraindicated in patients with CNS depression, use of adrenergic blockers, and carries additional risks of tardive dyskinesia, hypotension, tachycardia, and arrhythmias 2, 4